window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 25, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

non-small cell lung cancer

  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Kairos Pharma and Bayer to evaluate ENV-105 combination in prostate cancer

    Kairos Pharma and Bayer will evaluate ENV-105 in combination with [...]

    July 23, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Research & Development,Therapeutic Areas

    Kairos reports positive interim Phase 1 safety data for ENV-105 in EGFR-mutated lung cancer

    Kairos Pharma has reported positive interim safety results from an [...]

    July 16, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    Erasca reports encouraging Phase 1 data for ERAS-0015 and outlines Phase 3 cancer trials

    Erasca has reported updated preliminary Phase 1 data for its [...]

    July 14, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development,Therapeutic Areas

    Evogene partners QUT on AI drug discovery for lung cancer resistance

    Evogene Ltd has partnered with Queensland University of Technology to [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Evogene and Shanghai Lishan Biopharmaceuticals enter exclusive licensing agreement for BMC128

    Evogene Ltd and Shanghai Lishan Biopharmaceuticals Co. have entered into [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    Evogene licenses microbiome cancer therapy BMC128 to Shanghai Lishan Biopharmaceuticals

    Evogene and Shanghai Lishan Biopharmaceuticals have entered into an exclusive [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    NICE recommends amivantamab and lazertinib as first-line option for EGFR-mutated lung cancer

      The National Institute for Health and Care Excellence has [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    N4 Pharma and SRI demonstrate targeted Nuvec delivery to lung cancer cells

    N4 Pharma has reported new data from its collaboration with [...]

    May 5, 2026
  • Advanced Therapies,Drug Discovery & Development,Pharmaceuticals and therapeutics

    N4 Pharma advances targeted RNA delivery with SRI collaboration

    N4 Pharma plc, the UK biotech developing its proprietary Nuvec® [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Cemiplimab plus chemotherapy shows five-year survival benefit in advanced NSCLC Empower-lung 3 trial

    Regeneron UK Limited has reported five-year follow-up results from the [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Natus expands AI-powered EEG analysis across Europe
    Categories: Central Nervous System, Digital & Data, Medical devices
  • Enterome data link CD8 T-cell expansion to progression-free survival in lymphoma
    Categories: Advanced Therapies, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Telix starts Phase 3 trial of radiopharmaceutical therapy for renal cancer
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top